收藏切换
Protective effect of sacubitril valsartan combined with metoprolol on heart function in treatment of coronary atherosclerotic heart disease with chronic heart failure
收藏切换
Xia ZHANG1, Zhengzhang LI2, Ying XU3, Hui LI4, *
World Clinical Drug | 2022, 43(11) : 1462 - 1469
Less
收藏切换
World Clinical Drug | 2022, 43(11): 1462-1469
• Article •
Protective effect of sacubitril valsartan combined with metoprolol on heart function in treatment of coronary atherosclerotic heart disease with chronic heart failure
Full
Xia ZHANG1, Zhengzhang LI2, Ying XU3, Hui LI4, *
Affiliations
  • 1.Department of Pharmacy, Gaoyou People's Hospital, Yangzhou 225600, Jiangsu Province, China
  • 2.Department of Cardiovascular Medicine, Gaoyou People's Hospital, Yangzhou 225600, Jiangsu Province, China
  • 3.Department of Pharmacy, the 71st Group Army Hospital of the PLA, Xuzhou 221004, Jiangsu Province, China
  • 4.Department of Critical Medicine, Gaoyou People's Hospital, Yangzhou 225600, Jiangsu Province, China
Published: 2022-11-10 doi: 10.13683/j.wph.2022.11.013
Outline
收藏切换
Objective

To explore the protective effect of sacubitril valsartan combined with metoprolol in treatment of coronary atheroselerotic heart disease (CHD) with chronic heart failure (CHF).

Methods

A total of 180 patients with CHD and CHF were randomly divided into intervention group and control group, with 90 cases in each group. The control group were treated with angiotensin-converting enzyme inhibitor or angiotensin Ⅱ receptor antagonist combined with metoprolol, the intervention group were treated with sacubitril valsartan combined with metoprolol for 6 months. Clinical efficacy and major adverse cardiovascular events were compared between two groups. The left ventricular ejection fraction (LVEF), maximum early filling speed/maximum filling speed in late diastole (E/A), left ventricular end systolic diameter (LVESD), left ventricular end diastolic diameter (LVEDD) and left ventricular mass index (LVMI) were measured before and after treatment. The plasma N-terminal brain natriuretic peptide (NT-proBNP), serum cardiac troponin Ⅰ(cTn Ⅰ), creatine kinase isoenzyme (CK-MB), serum creatinine (Scr), cystatin C (CysC) and potassium were determined. The Minnesota living with heart failure questionnaire (MLHFQ) score, Lee's heart failure score and 6 min walking test (6MWT) were measured.

Results

Total effective rate of intervention group was significantly higher than that of control group (P<0.05). After treatment, there was no significant difference in blood pressure and heart rate between two groups (P>0.05), but the LVEF and E/A of intervention group were higher than those of control group, and LVEDD, LVESD, and LVMI were significantly lower than those of control group (P<0.05). After treatment, the levels of NT-proBNP, cTnⅠ, CK-MB and CysC in intervention group were significantly lower than those of control group (P<0.05), but there was no significant difference in Scr and potassium between two groups (P>0.05). After treatment, the 6MWT of intervention group was significantly higher than that of control group, while the MLHFQ and Lee's heart failure scores were significantly lower than those of control group (P<0.05). The follow-up results showed that the readmission rate for heart failure of intervention group were significantly lower than that of control group (P<0.05). The 2-year follow-up results showed that incidence of major adverse cardiovascular events (MACE) of intervention group were significantly lower than that of control group (P<0.05).

Conclusion

Sacubitril valsartan combined with metoprolol can improve the heart and kidney function of patients with CHD and CHF, inhibit left ventricular remodeling, improve exercise endurance and quality of life, and reduce the rate of MACE.

coronary heart disease  /  chronic heart failure  /  sacubitril valsartan  /  heart function
张霞, 李正章, 许英, 李慧. 沙库巴曲缬沙坦联合美托洛尔对冠状动脉粥样硬化性心脏病伴慢性心力衰竭的心功能保护作用研究. 世界临床药物, 2022 , 43 (11) : 1462 -1469 . DOI: 10.13683/j.wph.2022.11.013
Xia ZHANG, Zhengzhang LI, Ying XU, Hui LI. Protective effect of sacubitril valsartan combined with metoprolol on heart function in treatment of coronary atherosclerotic heart disease with chronic heart failure[J]. World Clinical Drug, 2022 , 43 (11) : 1462 -1469 . DOI: 10.13683/j.wph.2022.11.013
Year 2022 volume 43 Issue 11
11
2
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2022.11.013
  • Receive Date:2021-12-01
  • Online Date:2026-11-18
  • Published:2022-11-10
Article Data
Affiliations
History
  • Received:2021-12-01
  • Revised:2022-07-28
Funding
Affiliations
    1.Department of Pharmacy, Gaoyou People's Hospital, Yangzhou 225600, Jiangsu Province, China
    2.Department of Cardiovascular Medicine, Gaoyou People's Hospital, Yangzhou 225600, Jiangsu Province, China
    3.Department of Pharmacy, the 71st Group Army Hospital of the PLA, Xuzhou 221004, Jiangsu Province, China
    4.Department of Critical Medicine, Gaoyou People's Hospital, Yangzhou 225600, Jiangsu Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2022.11.013
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT